Evidence-Based Immune Supplements
Vitamin D: beyond the foundational discussion in the nutrition section, vitamin D’s immune role is the most clinically relevant for most people. Multiple RCTs show that vitamin D supplementation reduces acute respiratory infections by 12% overall and by 70% in profoundly deficient individuals. Mechanistically, vitamin D induces cathelicidin production (a broad-spectrum antimicrobial peptide), activates T cells (vitamin D is required for naive T cells to become effector T cells), and modulates the inflammatory response to prevent excessive immunopathology. Testing and targeting 40-60 ng/mL is the most important single immune supplement optimization strategy.
Zinc: an essential cofactor for over 100 immune-related enzymes, zinc lozenges (acetate or gluconate form) within the first 24 hours of cold symptoms reduce cold duration by 33-40% in meta-analyses of adequately controlled trials. The direct antimicrobial effect against rhinovirus in nasal passages requires direct mucosal contact — zinc lozenges, not capsules, are needed for this effect. For prevention, regular zinc intake from diet (oysters, beef, pumpkin seeds, legumes) is more important than supplementation; supplementing only when symptomatic or deficient is appropriate for most people. Excess zinc (>40mg daily long-term) can impair copper absorption and paradoxically impair immunity.
Elderberry (Sambucus nigra): systematic reviews of elderberry products find statistically significant reductions in cold and flu duration (average reduction of 3.86 days in one meta-analysis) and symptom severity. The mechanism involves flavonoids (particularly cyanidin-3-glucoside and cyanidin-3-sambubioside) that inhibit viral attachment to cells, stimulate cytokine production, and have direct antiviral activity. Quality and standardization matter significantly — the evidence base comes from standardized extracts; the effectiveness of commercial syrup products varies widely based on polyphenol content. Start at first symptoms for greatest effectiveness.
Probiotics for immunity: several specific probiotic strains have clinical trial evidence for reducing respiratory infection duration and severity. Lactobacillus rhamnosus GG (the most studied strain) reduces cold and respiratory infection incidence by 25% in children in multiple RCTs; effects in adults are less consistent but generally positive. Lactobacillus plantarum HEAL9 and Lactobacillus paracasei 8700:2, specifically studied for respiratory infection prevention, show 25-33% reduction in cold incidence and 2-day reduction in duration. The immune effects of probiotics are strain-specific — general “probiotic” products may not provide the same evidence-based outcomes as the specific strains studied in trials.